Drug Trial Radar · NCT04464980
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,516
Actual
Start
Jun 8, 2021
Primary completion
Dec 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- New York State Psychiatric Institute; Columbia University; Harvard Medical School (HMS and HSDM); Mclean Hospital; National Institute on Drug Abuse (NIDA); The Emmes Company, LLC
- First posted
- Jul 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Conditions
- Opioid Use Disorder (OUD)
Interventions
SL-BUPDrug
Daily dosing of sublingual buprenorphine-naloxone
XR-BUPDrug
Weekly/monthly dosing of extended-release injectable buprenorphine
XR-NTXDrug
Monthly dosing of extended-release injectable naltrexone
MMBehavioral
MM consists of standard Medical Management and the usual counseling at the treatment program.
MMRBehavioral
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
MMDBehavioral
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Retention: Continuous retention in MOUD treatment through 26 weeksTime frame: Retention: from randomization through week 26
- Discontinuation: Completed Discontinuation without RelapseTime frame: Discontinuation: from randomization through week 24 follow up
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
Little Rock, Arkansas
Tarzana Treatment Centers, Inc.
Tarzana, California
Liberation Programs, Inc.
Bridgeport, Connecticut
Operation PAR
Clearwater, Florida
Gateway Community Services
Jacksonville, Florida
Aspire Health Partners
Orlando, Florida
Mountain Manor / Maryland Treatment Centers
Baltimore, Maryland
McLean Hospital
Belmont, Massachusetts
Stanley Street Treatment and Resources, Inc.
Fall River, Massachusetts
Square Medical Group, LLC
Newton, Massachusetts
Gibson Center for Behavioral Change
Cape Girardeau, Missouri
Dartmouth Hitchcock - ATP
Lebanon, New Hampshire
University of New Mexico Addiction and Substance Abuse Program
Albuquerque, New Mexico
Bellevue Hospital Center
New York, New York
Adapt Integrated Health Care
Roseburg, Oregon
Adapt Integrated Health Care
Winston, Oregon
Center for Psychiatric and Chemical Dependency Services (CPCDS)
Pittsburgh, Pennsylvania
Internal Medicine Recovery Engagement Program (IM-REP)
Pittsburgh, Pennsylvania
Shoreline Behavioral Health Services
Conway, South Carolina
Huntsman Mental Health Institute / University of Utah
Salt Lake City, Utah
Chestnut Ridge Center
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.